Summary:
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.
Qualified Participants Must:
• 18 to 55 years of age
•
Diagnosis of RMS
Qualified Participants May Receive:
Compensation for time and travel.
Study-related care at no cost.